Annual EBITDA
-$39.08 M
-$31.62 M-424.30%
December 1, 2023
Summary
- As of February 7, 2025, CATX annual EBITDA is -$39.08 million, with the most recent change of -$31.62 million (-424.30%) on December 1, 2023.
- During the last 3 years, CATX annual EBITDA has fallen by -$35.79 million (-1088.44%).
- CATX annual EBITDA is now -114.24% below its all-time high of $274.37 million, reached on June 1, 2005.
Performance
CATX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$14.38 M
-$3.76 M-35.43%
September 1, 2024
Summary
- As of February 7, 2025, CATX quarterly EBITDA is -$14.38 million, with the most recent change of -$3.76 million (-35.43%) on September 1, 2024.
- Over the past year, CATX quarterly EBITDA has dropped by -$5.08 million (-54.68%).
- CATX quarterly EBITDA is now -4794766.67% below its all-time high of $300.00, reached on September 1, 2002.
Performance
CATX Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$47.81 M
-$5.08 M-11.90%
September 1, 2024
Summary
- As of February 7, 2025, CATX TTM EBITDA is -$47.81 million, with the most recent change of -$5.08 million (-11.90%) on September 1, 2024.
- Over the past year, CATX TTM EBITDA has dropped by -$20.09 million (-72.47%).
- CATX TTM EBITDA is now -1770640.74% below its all-time high of -$2700.00, reached on December 1, 1998.
Performance
CATX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
CATX EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -424.3% | -54.7% | -72.5% |
| 3 y3 years | -1088.4% | -56.2% | -210.7% |
| 5 y5 years | -659.9% | -56.2% | -210.7% |
CATX EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -1088.4% | at low | -996.3% | at low | -758.5% | at low |
| 5 y | 5-year | -1088.4% | at low | -2709.4% | at low | -1405.3% | at low |
| alltime | all time | -114.2% | at low | <-9999.0% | at low | <-9999.0% | at low |
Perspective Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$14.38 M(+35.4%) | -$47.81 M(+11.9%) |
| Jun 2024 | - | -$10.62 M(-7.2%) | -$42.73 M(+3.4%) |
| Mar 2024 | - | -$11.45 M(+0.8%) | -$41.32 M(+5.7%) |
| Dec 2023 | -$39.08 M(+424.3%) | -$11.36 M(+22.1%) | -$39.08 M(+41.0%) |
| Sep 2023 | - | -$9.30 M(+0.9%) | -$27.72 M(+22.9%) |
| Jun 2023 | - | -$9.21 M(+0.1%) | -$22.56 M(+46.6%) |
| Mar 2023 | - | -$9.21 M(+122.4%) | -$15.39 M(+69.7%) |
| Dec 2022 | -$7.45 M(+4.3%) | - | - |
| Sep 2022 | - | -$4.14 M(+102.8%) | -$9.07 M(+26.9%) |
| Jun 2022 | - | -$2.04 M(+55.6%) | -$7.14 M(+16.1%) |
| Jun 2022 | -$7.14 M(+117.2%) | - | - |
| Mar 2022 | - | -$1.31 M(-16.7%) | -$6.15 M(+10.5%) |
| Dec 2021 | - | -$1.57 M(-28.9%) | -$5.57 M(+15.5%) |
| Sep 2021 | - | -$2.21 M(+110.8%) | -$4.82 M(+46.7%) |
| Jun 2021 | -$3.29 M(-1.2%) | - | - |
| Jun 2021 | - | -$1.05 M(+44.4%) | -$3.29 M(-3.1%) |
| Mar 2021 | - | -$728.00 K(-12.2%) | -$3.39 M(+6.8%) |
| Dec 2020 | - | -$829.00 K(+21.9%) | -$3.18 M(-1.1%) |
| Sep 2020 | - | -$680.00 K(-41.1%) | -$3.21 M(-3.5%) |
| Jun 2020 | -$3.33 M(-35.3%) | -$1.16 M(+125.6%) | -$3.33 M(+1.4%) |
| Mar 2020 | - | -$512.00 K(-40.7%) | -$3.28 M(-15.8%) |
| Dec 2019 | - | -$864.00 K(+8.3%) | -$3.90 M(-12.5%) |
| Sep 2019 | - | -$798.00 K(-28.0%) | -$4.45 M(-13.4%) |
| Jun 2019 | -$5.14 M(-22.7%) | -$1.11 M(-1.9%) | -$5.14 M(-19.4%) |
| Mar 2019 | - | -$1.13 M(-20.4%) | -$6.38 M(-2.9%) |
| Dec 2018 | - | -$1.42 M(-4.5%) | -$6.57 M(-0.5%) |
| Sep 2018 | - | -$1.49 M(-36.7%) | -$6.60 M(-0.7%) |
| Jun 2018 | -$6.65 M(+6.5%) | -$2.35 M(+77.9%) | -$6.65 M(+8.1%) |
| Mar 2018 | - | -$1.32 M(-9.0%) | -$6.15 M(-0.8%) |
| Dec 2017 | - | -$1.45 M(-5.5%) | -$6.20 M(-0.2%) |
| Sep 2017 | - | -$1.53 M(-17.0%) | -$6.22 M(-0.4%) |
| Jun 2017 | -$6.24 M(+47.2%) | -$1.85 M(+34.8%) | -$6.24 M(+19.7%) |
| Mar 2017 | - | -$1.37 M(-6.3%) | -$5.22 M(+3.6%) |
| Dec 2016 | - | -$1.46 M(-6.2%) | -$5.03 M(+3.9%) |
| Sep 2016 | - | -$1.56 M(+89.4%) | -$4.84 M(+14.3%) |
| Jun 2016 | -$4.24 M(+36.6%) | -$823.00 K(-30.8%) | -$4.24 M(-1.8%) |
| Mar 2016 | - | -$1.19 M(-6.6%) | -$4.32 M(+9.4%) |
| Dec 2015 | - | -$1.27 M(+33.4%) | -$3.95 M(+14.6%) |
| Sep 2015 | - | -$954.00 K(+6.1%) | -$3.44 M(+11.0%) |
| Jun 2015 | -$3.10 M(-41.2%) | -$899.40 K(+9.8%) | -$3.10 M(-16.4%) |
| Mar 2015 | - | -$819.40 K(+6.2%) | -$3.71 M(-22.8%) |
| Dec 2014 | - | -$771.80 K(+26.0%) | -$4.81 M(+0.4%) |
| Sep 2014 | - | -$612.40 K(-59.4%) | -$4.79 M(-9.1%) |
| Jun 2014 | -$5.27 M(+69.1%) | -$1.51 M(-21.2%) | -$5.27 M(+15.1%) |
| Mar 2014 | - | -$1.92 M(+154.0%) | -$4.58 M(+42.9%) |
| Dec 2013 | - | -$754.00 K(-31.1%) | -$3.21 M(-6.4%) |
| Sep 2013 | - | -$1.09 M(+33.7%) | -$3.42 M(+9.8%) |
| Jun 2013 | -$3.12 M(+20.8%) | -$818.30 K(+51.7%) | -$3.12 M(-3.9%) |
| Mar 2013 | - | -$539.40 K(-44.5%) | -$3.24 M(+6.5%) |
| Dec 2012 | - | -$972.50 K(+23.5%) | -$3.05 M(+22.8%) |
| Sep 2012 | - | -$787.30 K(-16.7%) | -$2.48 M(-3.8%) |
| Jun 2012 | -$2.58 M(+24.4%) | -$945.70 K(+176.7%) | -$2.58 M(+18.3%) |
| Mar 2012 | - | -$341.80 K(-16.0%) | -$2.18 M(-5.6%) |
| Dec 2011 | - | -$407.10 K(-54.0%) | -$2.31 M(-0.2%) |
| Sep 2011 | - | -$885.50 K(+62.2%) | -$2.32 M(+11.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2011 | -$2.07 M(-31.9%) | -$546.00 K(+15.7%) | -$2.07 M(-12.1%) |
| Mar 2011 | - | -$472.00 K(+14.5%) | -$2.36 M(-14.0%) |
| Dec 2010 | - | -$412.40 K(-36.0%) | -$2.75 M(-9.6%) |
| Sep 2010 | - | -$644.00 K(-22.7%) | -$3.04 M(-0.3%) |
| Jun 2010 | -$3.04 M(-41.3%) | -$832.70 K(-2.7%) | -$3.04 M(-1.1%) |
| Mar 2010 | - | -$855.90 K(+21.7%) | -$3.08 M(-9.6%) |
| Dec 2009 | - | -$703.20 K(+7.8%) | -$3.40 M(-24.1%) |
| Sep 2009 | - | -$652.30 K(-24.7%) | -$4.48 M(-13.6%) |
| Jun 2009 | -$5.18 M(-33.0%) | -$865.70 K(-26.7%) | -$5.18 M(-4.5%) |
| Mar 2009 | - | -$1.18 M(-33.7%) | -$5.43 M(-11.5%) |
| Dec 2008 | - | -$1.78 M(+31.5%) | -$6.13 M(-11.7%) |
| Sep 2008 | - | -$1.35 M(+22.4%) | -$6.94 M(-10.4%) |
| Jun 2008 | -$7.74 M(-13.8%) | -$1.11 M(-41.2%) | -$7.74 M(-15.4%) |
| Mar 2008 | - | -$1.88 M(-27.3%) | -$9.15 M(-0.3%) |
| Dec 2007 | - | -$2.59 M(+19.9%) | -$9.17 M(+9.7%) |
| Sep 2007 | - | -$2.16 M(-14.2%) | -$8.36 M(-7.0%) |
| Jun 2007 | -$8.98 M(+37.4%) | -$2.52 M(+31.9%) | -$8.98 M(+5.1%) |
| Mar 2007 | - | -$1.91 M(+7.4%) | -$8.55 M(+7.6%) |
| Dec 2006 | - | -$1.78 M(-36.2%) | -$7.95 M(+4.3%) |
| Sep 2006 | - | -$2.79 M(+33.7%) | -$7.62 M(+16.4%) |
| Jun 2006 | -$6.54 M(-102.4%) | -$2.08 M(+60.1%) | -$6.54 M(+46.8%) |
| Mar 2006 | - | -$1.30 M(-10.0%) | -$4.46 M(+28.9%) |
| Dec 2005 | - | -$1.45 M(-15.4%) | -$3.46 M(+71.5%) |
| Sep 2005 | - | -$1.71 M(+466.1%) | -$2.02 M(+535.1%) |
| Jun 2005 | $274.37 M(<-9900.0%) | - | - |
| Mar 2005 | - | -$302.00 K(+8288.9%) | -$317.30 K(+1777.5%) |
| Dec 2004 | - | -$3600.00(-14.3%) | -$16.90 K(-29.9%) |
| Sep 2004 | -$9100.00(-52.1%) | -$4200.00(-44.0%) | -$24.10 K(-10.4%) |
| Jun 2004 | - | -$7500.00(+368.8%) | -$26.90 K(+26.9%) |
| Mar 2004 | - | -$1600.00(-85.2%) | -$21.20 K(-4.9%) |
| Dec 2003 | - | -$10.80 K(+54.3%) | -$22.30 K(+16.8%) |
| Sep 2003 | -$19.00 K(+150.0%) | -$7000.00(+288.9%) | -$19.10 K(+61.9%) |
| Jun 2003 | - | -$1800.00(-33.3%) | -$11.80 K(+2.6%) |
| Mar 2003 | - | -$2700.00(-64.5%) | -$11.50 K(-16.1%) |
| Dec 2002 | - | -$7600.00(-2633.3%) | -$13.70 K(+80.3%) |
| Sep 2002 | -$7600.00(-51.3%) | $300.00(-120.0%) | -$7600.00(-20.8%) |
| Jun 2002 | - | -$1500.00(-69.4%) | -$9600.00(-49.5%) |
| Mar 2002 | - | -$4900.00(+226.7%) | -$19.00 K(+25.8%) |
| Dec 2001 | - | -$1500.00(-11.8%) | -$15.10 K(-3.8%) |
| Sep 2001 | -$15.60 K(+10.6%) | -$1700.00(-84.4%) | -$15.70 K(-44.1%) |
| Jun 2001 | - | -$10.90 K(+990.0%) | -$28.10 K(+63.4%) |
| Mar 2001 | - | -$1000.00(-52.4%) | -$17.20 K(+6.2%) |
| Dec 2000 | - | -$2100.00(-85.1%) | -$16.20 K(+14.9%) |
| Sep 2000 | -$14.10 K(-9.0%) | -$14.10 K(<-9900.0%) | -$14.10 K(+11.9%) |
| Jun 2000 | - | $0.00(0.0%) | -$12.60 K(-5.3%) |
| Mar 2000 | - | $0.00(0.0%) | -$13.30 K(-3.6%) |
| Dec 1999 | - | $0.00(-100.0%) | -$13.80 K(-16.4%) |
| Sep 1999 | -$15.50 K(-93.0%) | -$12.60 K(+1700.0%) | -$16.50 K(+323.1%) |
| Jun 1999 | - | -$700.00(+40.0%) | -$3900.00(+21.9%) |
| Mar 1999 | - | -$500.00(-81.5%) | -$3200.00(+18.5%) |
| Dec 1998 | - | -$2700.00 | -$2700.00 |
| Sep 1998 | -$221.90 K(-25.5%) | - | - |
| Sep 1997 | -$297.90 K(-83.4%) | - | - |
| Sep 1996 | -$1.79 M(+326.4%) | - | - |
| Sep 1995 | -$420.50 K(-51.1%) | - | - |
| Sep 1994 | -$859.30 K | - | - |
FAQ
- What is Perspective Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Perspective Therapeutics?
- What is Perspective Therapeutics annual EBITDA year-on-year change?
- What is Perspective Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Perspective Therapeutics?
- What is Perspective Therapeutics quarterly EBITDA year-on-year change?
- What is Perspective Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Perspective Therapeutics?
- What is Perspective Therapeutics TTM EBITDA year-on-year change?
What is Perspective Therapeutics annual EBITDA?
The current annual EBITDA of CATX is -$39.08 M
What is the all time high annual EBITDA for Perspective Therapeutics?
Perspective Therapeutics all-time high annual EBITDA is $274.37 M
What is Perspective Therapeutics annual EBITDA year-on-year change?
Over the past year, CATX annual EBITDA has changed by -$31.62 M (-424.30%)
What is Perspective Therapeutics quarterly EBITDA?
The current quarterly EBITDA of CATX is -$14.38 M
What is the all time high quarterly EBITDA for Perspective Therapeutics?
Perspective Therapeutics all-time high quarterly EBITDA is $300.00
What is Perspective Therapeutics quarterly EBITDA year-on-year change?
Over the past year, CATX quarterly EBITDA has changed by -$5.08 M (-54.68%)
What is Perspective Therapeutics TTM EBITDA?
The current TTM EBITDA of CATX is -$47.81 M
What is the all time high TTM EBITDA for Perspective Therapeutics?
Perspective Therapeutics all-time high TTM EBITDA is -$2700.00
What is Perspective Therapeutics TTM EBITDA year-on-year change?
Over the past year, CATX TTM EBITDA has changed by -$20.09 M (-72.47%)